Background Medical Therapy and Clinical Outcomes from the VICTORIA Trial

Justin A. Ezekowitz*, Ciaran J. McMullan, Cynthia M. Westerhout, Ileana L. Piña, Jose Lopez-Sendon, Kevin J. Anstrom, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O'Connor, Burkert Pieske, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Joerg Koglin, Paul W. Armstrong, Javed Butler

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

4 Citaten (Scopus)
37 Downloads (Pure)

Samenvatting

BACKGROUND: We examined whether the primary composite outcome (cardiovascular death or heart failure hospitalization) was related to differences in background use and dosing of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), a randomized trial of vericiguat versus placebo. 

METHODS: We evaluated the adherence to guideline use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. We assessed basic adherence; indication-corrected adherence accounting for guideline indications and contraindications; and dose-corrected adherence (indication-corrected adherence+≥50% of drug dose target). Associations between study treatment and the primary composite outcome according to the adherence to guidelines were assessed using multivariable adjustment; adjusted hazard ratios with 95% CIs and Pinteractionare reported. 

RESULTS: Of 5050 patients, 5040 (99.8%) had medication data at baseline. For angiotensin-converting enzyme inhibitor, angiotensin-receptor blockers, and angiotensin receptor-neprilysin inhibitors, basic adherence to guidelines was 87.4%, indication-corrected was 95.7%, and dose-corrected was 50.9%. For beta-blockers, basic adherence was 93.1%, indication-corrected was 96.2%, and dose-corrected was 45.4%. For mineralocorticoid receptor antagonists, basic adherence was 70.3%, indication-corrected was 87.1%, and dose-corrected was 82.2%. For triple therapy (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin receptor-neprilysin inhibitors+beta-blocker+mineralocorticoid receptor antagonist), basic adherence was 59.7%, indication-corrected was 83.3%, and dose-corrected was 25.5%. Using basic or dose-corrected adherence, the treatment effect of vericiguat was consistent across adherence to guidelines groups, with or without multivariable adjustment with no treatment heterogeneity. 

CONCLUSIONS: Patients in VICTORIA were well treated with heart failure with reduced ejection fraction medications. The efficacy of vericiguat was consistent across background therapy with very high adherence to guidelines accounting for patient-level indications, contraindications, and tolerance. 

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02861534.

Originele taal-2English
Pagina's (van-tot)E010599
Aantal pagina's10
TijdschriftCirculation: Heart Failure
Volume16
Nummer van het tijdschrift9
DOI's
StatusPublished - sep.-2023

Vingerafdruk

Duik in de onderzoeksthema's van 'Background Medical Therapy and Clinical Outcomes from the VICTORIA Trial'. Samen vormen ze een unieke vingerafdruk.

Citeer dit